Eisai has begun to lay the groundwork for a slate of marketing applications in the U.S., Europe and Japan for a new thyroid cancer therapy after wrapping up a successful Phase III study of the drug, which is also noteworthy for relying on an innovative collaborative approach to the development process
Encouraged by the success of SFJ Pharmaceuticals in finding late-stage pharma assets that can be partnered and fast-tracked in Asia, Clarus Ventures and Abingworth have launched a new biotech drug developer with similar plans.
The life sciences industry gained a blast of good news on the venture front today. The National Venture Capital Association and PricewaterhouseCoopers outlined a buoyant set of numbers for the...
Pfizer and SFJ Pharmaceuticals will conduct Phase III trials for dacomitinib, a drug designed to treat non-small cell lung cancer.
SFJ Pharmaceuticals has garnered some major league venture backing for its plan to partner with the biopharma industry and take the lead on developing promising new drugs for the Asian market. And it's on its way to start paying off.
Japan's Eisai has struck an unusual deal with SFJ Pharmaceuticals to gain its financial backing for late-stage studies of an experimental cancer drug. SFJ will pay all the money needed for the trials